| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 40/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Bortezomib |
| Cas number | 179324-69-7 |
| Apperance | White or off-white powder |
| MF | C19H25BN4O4 |
| MW | 384.23700 |
Bortezomib was the first proteasome inhibitor to be used clinically. The proteasome is present in all eukaryotic cells and degrades over 80% of the proteins in the cell. It can reversibly inhibit the function of proteasome, thus inhibiting the Chemicalbook solution of protein, leading to protein accumulation and apoptosis. Because multiple myeloma (MM) continually replicates and secretes myeloma proteins, it is more sensitive to proteasomes than normal cells and can be used as a second-line treatment for MM and mantle cell lymphoma.
Bortezomib is a reversible inhibitor of the chymase-like activity of 26S protease in mammalian cells. In vitro tests demonstrated that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor models In vivo testing demonstrates that bortezomib delays tumor growth, including multiple myeloma. This product is used in the treatment of patients with multiple myeloma, the effectiveness is based on its efficiency.
Bortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells.
){kind=link}